NCS 382

structure given in first source

Also Known As:

(E)-2-(5-Hydroxy-5,7,8,9-tetrahydro-6H-benzo(7)annulen-6-ylidene)acetic acid; 6,7,8,9-tetrahydro-5-(H)-benzocycloheptene-5-ol-4-ylideneacetic acid; Acetic acid, (5,7,8,9-tetrahydro-5-hydroxy-6H-benzocyclohepten-6-ylidene)-, monosodium salt; NCS 382 85; NCS 38285; NCS-382; NCS-38285; NCS382

Networked: 10 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gibson, K Michael: 2 articles (12/2016 - 07/2002)
2.	Froestl, Wolfgang: 2 articles (07/2005 - 07/2002)
3.	Follman, Kristin E: 1 article (05/2022)
4.	Morris, Marilyn E: 1 article (05/2022)
5.	Ainslie, G R: 1 article (02/2018)
6.	Gibson, K M: 1 article (02/2018)
7.	McConnell, A: 1 article (02/2018)
8.	Roullet, J-B: 1 article (02/2018)
9.	Vogel, K R: 1 article (02/2018)
10.	Ainslie, Garrett R: 1 article (12/2016)

Related Diseases

1.	Memory Disorders (Memory Loss) 01/01/2016 - "Improvement in γ-hydroxybutyrate-induced contextual fear memory deficit by systemic administration of NCS-382."
2.	Ataxia (Dyssynergia) 01/01/2004 - "As revealed by several behavioral studies, NCS-382 fails to antagonize GHB discriminative stimuli, GHB-induced inhibition of locomotor activity and ataxia or suppression of operant responses. " 07/01/2005 - "Some doses of NCS-382 appeared to exacerbate ataxia and gastrointestinal discomfort produced by GHB in some subjects. "
3.	succinic semialdehyde dehydrogenase deficiency 02/01/2018 - "The cumulative data provides increasing confidence that NCS-382 could eventually be considered in the therapeutic armament for heritable SSADH deficiency." 07/01/2002 - "We conclude that taurine and NCS-382 may have therapeutic relevance in human SSADH deficiency and that the poor clinical efficacy of VGB in this disease may relate to an inability to decrease brain GHB concentrations." 12/01/2016 - "NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzo-cyclohept-6-ylideneacetic acid), a known GHB receptor antagonist, has shown significant efficacy in a murine model of succinic semialdehyde dehydrogenase deficiency (SSADHD), a heritable neurological disorder featuring chronic elevation of GHB that blocks the final step of GABA degradation. " 02/01/2018 - "Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder."
4.	Seizures (Absence Seizure) 01/01/1996 - "The object of these experiments was to examine the effectiveness of a range of specific GABAB-receptor agonists and antagonists of varying specificity, as well as the specific GHB-receptor antagonist NCS 382, in two experimental animal models of generalized absence seizures: one in which the seizures are induced by GHB and the other in which the seizures are induced by administration of low-dose (20-mg/kg) pentylenetetrazole. " 05/03/2022 - "The tremors/seizures occurred in a manner that was dependent on both the dose and timing of SGS742 administration, and were not altered with pretreatment with gabazine, a GABAA receptor inhibitor, and only partially reduced with pretreatment with NCS382, a selective GHB receptor antagonist. "
5.	Tremor (Tremors) 05/03/2022 - "The tremors/seizures occurred in a manner that was dependent on both the dose and timing of SGS742 administration, and were not altered with pretreatment with gabazine, a GABAA receptor inhibitor, and only partially reduced with pretreatment with NCS382, a selective GHB receptor antagonist. "

Related Drugs and Biologics

1.	gamma-Aminobutyric Acid (GABA)
2.	NCS 382
3.	Taurine
4.	Superoxides (Superoxide)
5.	Pentylenetetrazole (Metrazol)
6.	Oxygen (Dioxygen)
7.	Nimodipine (Modus)
8.	Ligands
9.	Enzymes
10.	Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1.	Intraperitoneal Injections
2.	Injections